{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T18:33:36Z","timestamp":1766428416722,"version":"3.40.4"},"reference-count":24,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologica"],"published-print":{"date-parts":[[2014]]},"abstract":"<b><i>Objective:<\/i><\/b> To compare outcomes after switching from intravitreal ranibizumab to bevacizumab in neovascular age-related macular degeneration (AMD). <b><i>Methods:<\/i><\/b> A retrospective review of 110 eyes treated in a 1+PRN (pro re nata) clinical setting with ranibizumab that were switched to bevacizumab. Patients analyzed had at least 3 ranibizumab injections followed by at least 3 bevacizumab injections. Changes in best-corrected visual acuity (BCVA), retinal thickness and frequency of injections were compared. <b><i>Results:<\/i><\/b> The mean duration of ranibizumab treatment was 18.1 months, followed by 12.2 months of bevacizumab. Mean injection rates per month were similar (0.54 and 0.56 respectively, p = 0.230). There were no significant differences between BCVA at baseline and at the time of the switch (52.4 and 54.8 letters, p = 0.059). After the switch, there was a statistically significant decrease in BCVA to 51.7 letters (p < 0.001). <b><i>Conclusion:<\/i><\/b> Switching patients to bevacizumab may have a minor negative effect on the initial gain obtained with ranibizumab; however the degenerative history of wet AMD could explain this small variation in visual acuity.<\/jats:p>","DOI":"10.1159\/000363422","type":"journal-article","created":{"date-parts":[[2014,9,9]],"date-time":"2014-09-09T07:51:33Z","timestamp":1410249093000},"page":"149-155","source":"Crossref","is-referenced-by-count":8,"title":["Switch from Intravitreal Ranibizumab to Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration: Clinical Comparison"],"prefix":"10.1159","volume":"232","author":[{"given":"Jo\u00e3o","family":"Pinheiro-Costa","sequence":"first","affiliation":[]},{"given":"Paulo","family":"Freitas-da-Costa","sequence":"additional","affiliation":[]},{"given":"Manuel S.","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"given":"Elisete M.","family":"Brand\u00e3o","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Falc\u00e3o-Reis","sequence":"additional","affiliation":[]},{"given":"\u00c2ngela M.","family":"Carneiro","sequence":"additional","affiliation":[]}],"member":"127","published-online":{"date-parts":[[2014,8,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.11.1621"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2003.11.069"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200502000-00001"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181b1bb06"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.02240.x"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.66"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181c700a9"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.159160"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.11.019"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200604000-00001"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000225766.75009.3a"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.09.031"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S33017"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.04.015"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2012.01.003"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32834595d0"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3928\/15428877-20100303-05"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S8367"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1159\/000343709"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4774"}],"container-title":["Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/363422","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/363422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:48:49Z","timestamp":1745430529000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000363422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,11,1]]},"published-print":{"date-parts":[[2014,11,18]]}},"URL":"https:\/\/doi.org\/10.1159\/000363422","archive":["Portico"],"relation":{},"ISSN":["0030-3755","1423-0267"],"issn-type":[{"type":"print","value":"0030-3755"},{"type":"electronic","value":"1423-0267"}],"subject":[],"published":{"date-parts":[[2014]]}}}